- Financing wraps up: BMS priced €5 billion of senior unsecured notes in five tranches; closing is expected Monday, Nov. 10. Proceeds will help fund a multi‑tranche debt tender offer that runs to Dec. 3 (early tender Nov. 17). 1
- Legal overhang addressed: A $239 million settlement of a long‑running class action tied to legacy Celgene disclosures was filed Nov. 5; it requires court approval. 2
- Partner cash already flowing:BioNTech lifted its 2025 revenue guidance after receiving initial payments from the new BMS immuno‑oncology alliance. 3
- Data weekend for Camzyos: At AHA Scientific Sessions (Nov. 7–10), BMS is presenting long‑term and real‑world data for Camzyos (mavacamten) in obstructive HCM. 4
- Competitive & generic currents: A fresh generic approval for dasatinib (Sprycel) landed Nov. 7, and a startup raised funding to challenge Camzyos in HCM. 5
Financing & balance sheet: euro notes + tender offer
Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. 1
Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding accrued coupons. 6
Why it matters: With near‑term maturities and higher‑coupon legacy debt, the pair of transactions gives BMS flexibility to reprofile liabilities while it invests behind late‑stage assets and partnerships.
Litigation: Celgene class action settlement filed
On Nov. 5, BMS agreed to a $239 million settlement resolving claims that Celgene misled investors about prospects for Otezla and ozanimod (Zeposia) ahead of BMS’s 2019 acquisition. After fees, about $159.3 million could go to the class, pending court approval. BMS denied wrongdoing; the settlement removes a legal distraction. 2
Pipelines & data catalysts: cardio this weekend, cell therapy next
- Camzyos at AHA 2025 (Nov. 7–10): BMS is showcasing an extension study approaching 4 years and multiple real‑world analyses (including U.S. REMS data) in obstructive HCM, plus updates from the milvexian collaboration with J&J in thrombosis. Today (Nov. 9) sits in the middle of the meeting; additional Camzyos‑related presentations run through Monday, Nov. 10. 4
- Breyanzi (liso‑cel) — upcoming FDA decision: The sBLA in marginal zone lymphoma is under Priority Review with an action date of Dec. 5, 2025, a near‑term regulatory catalyst. 7
- Sprycel (dasatinib) pressure: The FDA approved generic dasatinib tablets (multiple strengths) on Nov. 7, adding to competitive intensity in CML/ALL and underscoring the importance of BMS’s “new product” cohort offsetting LOE headwinds. 5
Partner ecosystem: BioNTech payments arrive; new solid‑tumor experiment
- BioNTech collaboration: BioNTech raised 2025 revenue guidance to €2.6–€2.8B after receiving initial payments from BMS tied to their bispecific PD‑L1/VEGF program (pumitamig/BNT327), with more studies slated in 2026. This follows BMS’s commitment of up to $11.1B in total economics earlier this year. 3
- Dispatch Bio clinical‑supply deal: BMS will supply ide‑cel (Abecma) for Dispatch Bio’s planned Phase 1 U.S. study in solid tumors starting 2026 — a first‑of‑its‑kind clinical‑supply pact using an autologous CAR‑T in combination with a tumor‑targeting viral approach. 8
Earnings context: Q3 scorecard sets the stage
Just ahead of this week’s financing, BMS beat Q3 revenue and EPS expectations, helped by Opdivo (including initial subcutaneous uptake) and Eliquis, while the “growth portfolio” offset steep Revlimid erosion. Headline figures: Revenue $12.22B (vs. $11.8B est.), adj. EPS $1.63; Opdivo $2.53B (+$67M from SC launch), Eliquis $3.75B. 9
Competitive notes to watch
- Hypertrophic cardiomyopathy:Braveheart Bio raised $185M (Nov. 5) to advance an HCM therapy licensed from Hengrui, aiming to challenge Camzyos — a reminder that Camzyos’s lead will face follow‑on entrants. 10
Dates & deadlines (all in 2025)
- AHA Scientific Sessions: Nov. 7–10 (Camzyos & milvexian data). 4
- €5B notes closing:Nov. 10 (expected). 1
- Debt tender offers: Early tender Nov. 17; final expiration Dec. 3. 6
- FDA action date — Breyanzi (MZL):Dec. 5. 7
Bottom line
On November 9, 2025, Bristol‑Myers Squibb sits at the intersection of capital structure cleanup (euro notes + tender), pipeline proof points (Camzyos at AHA; Breyanzi PDUFA next), and partner‑powered momentum (BioNTech payments starting to hit). Legal risk is reduced via the Celgene settlement filing, while generic and competitive pressures reinforce why BMS is leaning into late‑stage assets and alliances. Near‑term investor focus: notes closing Monday, tender early‑tender participation, and Dec. 5 FDA outcome for Breyanzi. 1
This article is for information purposes only and is not investment advice.
